POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

Overview of attention for article published in Journal of Clinical Oncology, May 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 1 X post from an account with 597 followers.

I haven’t mentioned the POLARIX Trial yet, although Roche announced that it met it’s endpoints the data hasn’t been submitted yet. But it’s a Phase 3 trial comparing Pola + R-CHP vs R-CHOP in patients with previously untreated DLBCL https://t.co/UsGTwAcM…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.